4/9
08:37 am
gnpx
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting [Yahoo! Finance]
Medium
Report
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting [Yahoo! Finance]
4/9
08:31 am
gnpx
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Low
Report
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
4/4
10:34 am
gnpx
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up [Yahoo! Finance]
Low
Report
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up [Yahoo! Finance]
4/3
08:38 am
gnpx
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer [Yahoo! Finance]
Low
Report
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer [Yahoo! Finance]
4/3
08:31 am
gnpx
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Medium
Report
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
4/3
08:08 am
gnpx
Genprex, Inc. (NASDAQ: GNPX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Genprex, Inc. (NASDAQ: GNPX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
4/2
08:48 am
gnpx
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System [Yahoo! Finance]
Low
Report
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System [Yahoo! Finance]
4/2
08:31 am
gnpx
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
Medium
Report
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
3/25
08:07 am
gnpx
Genprex, Inc. (NASDAQ: GNPX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $10.00 price target on the stock.
Medium
Report
Genprex, Inc. (NASDAQ: GNPX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $10.00 price target on the stock.
3/22
04:10 pm
gnpx
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Medium
Report
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
3/19
01:24 pm
gnpx
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Low
Report
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
3/19
08:45 am
gnpx
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]
High
Report
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]
3/19
08:36 am
gnpx
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Medium
Report
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
3/12
09:28 am
gnpx
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers [Yahoo! Finance]
Medium
Report
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers [Yahoo! Finance]
3/12
09:01 am
gnpx
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
High
Report
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
3/6
08:51 am
gnpx
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting [Yahoo! Finance]
High
Report
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting [Yahoo! Finance]
3/6
08:30 am
gnpx
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Low
Report
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
2/7
08:30 am
gnpx
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators [Yahoo! Finance]
High
Report
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators [Yahoo! Finance]
2/7
08:15 am
gnpx
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
High
Report
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
2/6
07:30 am
gnpx
Genprex to Present at Upcoming BIO CEO & Investor Conference
Medium
Report
Genprex to Present at Upcoming BIO CEO & Investor Conference
2/5
07:39 am
gnpx
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer [Yahoo! Finance]
Low
Report
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer [Yahoo! Finance]
2/5
07:30 am
gnpx
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Low
Report
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
1/31
08:59 am
gnpx
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024 [Yahoo! Finance]
High
Report
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024 [Yahoo! Finance]
1/31
08:42 am
gnpx
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024
High
Report
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024